Free Trial
NASDAQ:RANI

Rani Therapeutics (RANI) Stock Price, News & Analysis

Rani Therapeutics logo
$0.53 +0.00 (+0.21%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$0.52 -0.01 (-1.58%)
As of 11/13/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Rani Therapeutics Stock (NASDAQ:RANI)

Advanced

Key Stats

Today's Range
$0.50
▼
$0.54
50-Day Range
$0.52
▼
$0.87
52-Week Range
$0.50
▼
$1.99
Volume
521,249 shs
Average Volume
488,523 shs
Market Capitalization
$73.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.33
Consensus Rating
Moderate Buy

Company Overview

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company developing technology to deliver biologic medicines orally. Its RaniPill platform is designed to transport drugs such as peptides and antibodies through the digestive system and release them into the intestinal wall, with the goal of offering an alternative to injections.

Founded in 2012 and based in San Jose, California, the company develops its delivery platform and evaluates it with drug candidates and potential partner medicines. Rani’s work focuses on addressing challenges that have traditionally made many biologic drugs difficult to administer by mouth.

AI Generated. May Contain Errors.

Rani Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
43rd Percentile Overall Score

RANI MarketRank™: 
2.13750492967 of 5 stars

Rani Therapeutics scored higher than 43% of companies evaluated by MarketBeat, and ranked 642nd out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Rani Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Rani Therapeutics has a consensus price target of $8.33, representing about 1,483.4% upside from its current price of $0.53.

  • Amount of Analyst Coverage

    Rani Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Rani Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Rani Therapeutics are expected to decrease in the coming year, from ($0.17) to ($0.20) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Rani Therapeutics is -2.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Rani Therapeutics is -2.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Rani Therapeutics has a P/B Ratio of 1.55. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    8.05% of the float of Rani Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Rani Therapeutics has a short interest ratio ("days to cover") of 17.2, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Rani Therapeutics has recently increased by 0.76%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Rani Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Rani Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Rani Therapeutics has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Rani Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    2 people have searched for RANI on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Rani Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Rani Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    26.73% of the stock of Rani Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    30.19% of the stock of Rani Therapeutics is held by institutions.

  • Read more about Rani Therapeutics' insider trading history.
Receive RANI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rani Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

RANI Stock News Headlines

A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.tc pixel
Rani Therapeutics (RANI) Expected to Release Earnings on Thursday
See More Headlines

RANI Stock Analysis - Frequently Asked Questions

Rani Therapeutics' stock was trading at $1.35 on January 1st, 2026. Since then, RANI stock has decreased by 61.0% and is now trading at $0.5263.

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) released its quarterly earnings data on Monday, November, 9th. The company reported ($0.04) earnings per share for the quarter, topping analysts' consensus estimates of ($0.05) by $0.01. The firm had revenue of $1.71 million for the quarter, compared to the consensus estimate of $1.28 million. Rani Therapeutics had a negative net margin of 493.00% and a negative trailing twelve-month return on equity of 76.64%.

Rani Therapeutics (RANI) raised $100 million in an initial public offering (IPO) on Thursday, July 29th 2021. The company issued 6,666,667 shares at a price of $14.00-$16.00 per share.

Rani Therapeutics' top institutional investors include State Street Corp (0.28%) and Marshall Wace LLP (0.24%). Insiders that own company stock include South Cone Investments Limited, Mir A Imran, Talat Imran, Kate Mckinley, Alireza Javadi and Cortes Isidoro Alfonso Quiroga.
View institutional ownership trends
.

Shares of RANI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Rani Therapeutics investors own include Palantir Technologies (PLTR), Plug Power (PLUG), D-Wave Quantum (QBTS), Rocket Lab (RKLB), Oracle (ORCL), Bitfarms (BITF) and Datavault AI (DVLT).

Company Calendar

Last Earnings
11/09/2026
Today
11/15/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:RANI
CIK
1856725
Fax
N/A
Employees
69
Year Founded
2012

Price Target and Rating

High Price Target
$11.00
Low Price Target
$5.00
Potential Upside/Downside
+1,483.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.19)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$29.67 million
Net Margins
-493.00%
Pretax Margin
-521.20%
Return on Equity
-76.64%
Return on Assets
-56.97%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.26
Quick Ratio
5.31

Sales & Book Value

Annual Sales
$1.63 million
Price / Sales
45.01
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.30 per share
Price / Book
1.75

Miscellaneous

Outstanding Shares
139,400,000
Free Float
102,135,000
Market Cap
$73.37 million
Optionable
Optionable
Beta
0.61

Social Links

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:RANI) was last updated on 11/13/2026 by MarketBeat.com Staff.
From Our Partners